Cell Growth & Differentiation, Vol 7, Issue 12 1617-1623, Copyright © 1996 by American Association of Cancer Research

ARTICLES

Enforced expression of Bcl-XS induces differentiation and sensitizes chronic myelogenous leukemia-blast crisis K562 cells to 1-beta-D-arabinofuranosylcytosine-mediated differentiation and apoptosis

S Ray, G Bullock, G Nunez, C Tang, AM Ibrado, Y Huang and K Bhalla
Department of Medicine, Winship Cancer Center, Emory University School of Medicine, Atlenta, Georgia 30322, USA.

Human chronic myelogenous leukemia-blast crisis K562 cells have been demonstrated to be relatively resistant to antileukemic drug-induced apoptosis. This has been attributed to the activity of p210bcr-abl tyrosine kinase present in the K562 cells, which is known to suppress drug-induced apoptosis. Recently, K562 cells have been shown to express the antiapoptosis Bcl-xL but not Bcl-2 proteins. To investigate the contribution of Bcl-xL toward resistance to drug-induced apoptosis, we created K562/Bcl-xS and K562/neo cells by electroporating the expression plasmids pSFFVneo-Bcl-xS and pSFFVneo, containing the bcl-xS and neomycin resistance genes, respectively, into K562 cells. K562/Bcl-xS but not K562/neo cells expressed the bcl-xS mRNA and p19Bcl-xS protein. In contrast, both cell types expressed equivalent levels of Bcl-xL, Bax, Bcl-2, Myc, retinoblastoma, p21cbor-abl, and p145abl proteins. A significant increase in the hemoglobin levels was observed in the K562/Bcl-xS compared with the K562/neo cells (P < 0.05). In addition, K562/Bcl-xS cells were significantly more sensitive than K562/neo cells to undergoing erythroid differentiation induced by low-dose 1-beta-D-arabinofuranosylcytosine (ara-C) and hexamethyl bisacetamide (P < 0.05), but not by all-trans-retinoic acid. Low-dose ara-C- or hexamethyl bisacetamide-induced differentiation was not associated with apoptosis of K562/Bcl-xS or K562/neo cells. Low-dose ara-C-induced erythroid differentiation was accompanied by conversion of the retinoblastoma protein to predominantly its underphosphorylated isoform as well as by down-regulation of Myc levels in K562/Bcl-xS and K562/neo cells. Importantly, exposure to high-dose ara-C (HIDAC; 100 microM ara-C for 4 h) caused internucleosomal DNA fragmentation and the morphological features of apoptosis in K562/Bcl-xS cells. These effects were modestly enhanced by cotreatment with HIDAC plus herbimycin A. In contrast, K562/neo cells were completely resistant to HIDAC- and herbimycin A-induced apoptosis. These results indicate that the expression of Bcl-xS induces erythroid differentiation and partially sensitizes chronic myelogenous leukemia-blast crisis-derived K562 cells to ara-C-induced differentiation and apoptosis.

This article has been cited by other articles:

				J.-W. Cheong, S. Y. Chong, J. Y. Kim, J. I. Eom, H. K. Jeung, H. Y. Maeng, S. T. Lee, and Y. H. Min Induction of Apoptosis by Apicidin, a Histone Deacetylase Inhibitor, via the Activation of Mitochondria-Dependent Caspase Cascades in Human Bcr-Abl-Positive Leukemia Cells Clin. Cancer Res., October 15, 2003; 9(13): 5018 - 5027. [Abstract] [Full Text] [PDF]

				K. Hafid-Medheb, Y. Augery-Bourget, M.-N. Minatchy, N. Hanania, and J. Robert-Lezenes Bcl-XL is required for heme synthesis during the chemical induction of erythroid differentiation of murine erythroleukemia cells independently of its antiapoptotic function Blood, April 1, 2003; 101(7): 2575 - 2583. [Abstract] [Full Text] [PDF]

				R. Nimmanapalli, E. O'Bryan, M. Huang, P. Bali, P. K. Burnette, T. Loughran, J. Tepperberg, R. Jove, and K. Bhalla Molecular Characterization and Sensitivity of STI-571 (Imatinib Mesylate, Gleevec)-resistant, Bcr-Abl-positive, Human Acute Leukemia Cells to SRC Kinase Inhibitor PD180970 and 17-Allylamino-17-demethoxygeldanamycin Cancer Res., October 15, 2002; 62(20): 5761 - 5769. [Abstract] [Full Text] [PDF]

				R. Nimmanapalli, E. O’Bryan, and K. Bhalla Geldanamycin and Its Analogue 17-Allylamino-17-demethoxygeldanamycin Lowers Bcr-Abl Levels and Induces Apoptosis and Differentiation of Bcr-Abl-positive Human Leukemic Blasts Cancer Res., March 1, 2001; 61(5): 1799 - 1804. [Abstract] [Full Text]

				R. Nimmanapalli, M. Porosnicu, D. Nguyen, E. Worthington, E. O’Bryan, C. Perkins, and K. Bhalla Cotreatment with STI-571 Enhances Tumor Necrosis Factor {{alpha}}-related Apoptosis-inducing Ligand (TRAIL or Apo-2L)- induced Apoptosis of Bcr-Abl-positive Human Acute Leukemia Cells Clin. Cancer Res., February 1, 2001; 7(2): 350 - 357. [Abstract] [Full Text]

				G. Fang, C. N. Kim, C. L. Perkins, N. Ramadevi, E. Winton, S. Wittmann, and K. N. Bhalla CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs Blood, September 15, 2000; 96(6): 2246 - 2253. [Abstract] [Full Text] [PDF]

				M. Horita, E. J. Andreu, A. Benito, C. Arbona, C. Sanz, I. Benet, F. Prosper, and J. L. Fernandez-Luna Blockade of the Bcr-Abl Kinase Activity Induces Apoptosis of Chronic Myelogenous Leukemia Cells by Suppressing Signal Transducer and Activator of Transcription 5-dependent Expression of Bcl-xL J. Exp. Med., March 13, 2000; 191(6): 977 - 984. [Abstract] [Full Text] [PDF]

				C. Perkins, C. N. Kim, G. Fang, and K. N. Bhalla Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-xL Blood, February 1, 2000; 95(3): 1014 - 1022. [Abstract] [Full Text] [PDF]

				P. A. Svingen, A. Tefferi, T. J. Kottke, G. Kaur, V. L. Narayanan, E. A. Sausville, and S. H. Kaufmann Effects of the bcr/abl Kinase Inhibitors AG957 and NSC 680410 on Chronic Myelogenous Leukemia Cells in Vitro Clin. Cancer Res., January 1, 2000; 6(1): 237 - 249. [Abstract] [Full Text]

				S. Hatse, D. Schols, E. D. Clercq, and J. Balzarini 9-(2-Phosphonylmethoxyethyl)adenine Induces Tumor Cell Differentiation or Cell Death by Blocking Cell Cycle Progression through the S Phase Cell Growth Differ., June 1, 1999; 10(6): 435 - 446. [Abstract] [Full Text]

				G. P. Amarante-Mendes, C. Naekyung Kim, L. Liu, Y. Huang, C. L. Perkins, D. R. Green, and K. Bhalla Bcr-Abl Exerts Its Antiapoptotic Effect Against Diverse Apoptotic Stimuli Through Blockage of Mitochondrial Release of Cytochrome C and Activation of Caspase-3 Blood, March 1, 1998; 91(5): 1700 - 1705. [Abstract] [Full Text] [PDF]

				L. M. Martins, P. W. Mesner, T. J. Kottke, G. S. Basi, S. Sinha, J. S. Tung, P. A. Svingen, B. J. Madden, A. Takahashi, D. J. McCormick, et al. Comparison of Caspase Activation and Subcellular Localization in HL-60 and K562 Cells Undergoing Etoposide-Induced Apoptosis Blood, December 1, 1997; 90(11): 4283 - 4296. [Abstract] [Full Text] [PDF]

				L. Li, M. J. Keating, W. Plunkett, and L.-Y. Yang Fludarabine-Mediated Repair Inhibition of Cisplatin-Induced DNA Lesions in Human Chronic Myelogenous Leukemia-Blast Crisis K562 Cells: Induction of Synergistic Cytotoxicity Independent of Reversal of Apoptosis Resistance Mol. Pharmacol., November 1, 1997; 52(5): 798 - 806. [Abstract] [Full Text]

				N. R. Murray and A. P. Fields Atypical Protein Kinase C iota  Protects Human Leukemia Cells against Drug-induced Apoptosis J. Biol. Chem., October 31, 1997; 272(44): 27521 - 27524. [Abstract] [Full Text] [PDF]